Clinical Trial Detail


Missing content? – Request curation!

Request curation for specific Genes, variants, or PubMed publications.

Have questions, comments or suggestions? - Let us know!

Email us at :

NCT ID NCT05255471
Title MITO 35B: Olaparib Beyond Progression Compared to Platinum Chemotherapy After Secondary Cytoreductive Surgery in Recurrent Ovarian Cancer Patients. (MITO 35B)
Recruitment Recruiting
Gender female
Phase Phase III
Variant Requirements No
Sponsors National Cancer Institute, Naples

fallopian tube cancer

peritoneum cancer

ovarian cancer


Carboplatin + Paclitaxel


Carboplatin + Pegylated liposomal-doxorubicin

Carboplatin + Gemcitabine

Age Groups: adult | senior
Covered Countries ITA

No variant requirements are available.